Garo H. Armen - May 5, 2023 Form 4/A - Amendment Insider Report for MiNK Therapeutics, Inc. (INKT)

Role: Director
Signature: By: /s/ Christine Klaskin, Attorney-in-Fact for Garo H. Armen
Stock symbol: INKT
Transactions as of: May 5, 2023
Transactions value $: $0
Form type: 4/A - Amendment
Date filed: 5/26/2023, 05:29 PM
Date Of Original Report: May 5, 2023
Previous filing: May 4, 2023
Next filing: Sep 11, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	INKT	Common Stock						1.97M	May 5, 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On May 5, 2023, Garo Armen, the CEO and Chairman of Agenus, disclosed a transaction involving 100,000 MiNK Therapeutics shares. He agreed to sell these shares to Agenus at his original purchase price, which was lower than the market price at the time of the proposed sale. This action was taken to prevent any perception of Dr. Armen benefitting from low-cost purchases while Agenus was buying at higher prices in separate transactions. However, due to the shares being in Dr. Armen's IRA account, their transfer was prohibited, leading the broker to reverse the sale and decline Agenus' payment. Consequently, the MiNK Therapeutics shares were returned to Dr. Armen, and the sale price was given back to Agenus. This amendment accounts for the changes in Dr. Armen's share ownership following the reversal of this transaction.

Content

On May 5, 2023, Garo Armen, the CEO and Chairman of Agenus, disclosed a transaction involving 100,000 MiNK Therapeutics shares. He agreed to sell these shares to Agenus at his original purchase price, which was lower than the market price at the time of the proposed sale. This action was taken to prevent any perception of Dr. Armen benefitting from low-cost purchases while Agenus was buying at higher prices in separate transactions. However, due to the shares being in Dr. Armen's IRA account, their transfer was prohibited, leading the broker to reverse the sale and decline Agenus' payment. Consequently, the MiNK Therapeutics shares were returned to Dr. Armen, and the sale price was given back to Agenus. This amendment accounts for the changes in Dr. Armen's share ownership following the reversal of this transaction.